ROCKET PHARMACEUTICALS, INC. Annual Report - A Deep Dive for Investors

Imagine a world where devastating genetic diseases are not just managed, but cured. Rocket Pharmaceuticals is on a mission to transform the lives of patients suffering from ultra-rare genetic diseases, and this report offers a clear, comprehensive look at its performance for the fiscal year ended December 31, 2025. We'll explore the company's progress, financial health, and future prospects, helping you understand its investment potential.

Business Overview: Leading the Charge in Gene Therapy

Rocket Pharmaceuticals stands at the forefront of gene therapy, developing groundbreaking treatments for devastating and extremely rare genetic diseases. Its goal is to correct the root cause of these conditions by delivering healthy genes to patients. Rocket focuses on diseases with significant unmet medical needs, including:

• LAD-I (Leukocyte Adhesion Deficiency-I): A severe immune disorder.
• Danon Disease: A progressive, often fatal, heart condition.
• PKD (Pyruvate Kinase Deficiency): A rare inherited anemia.
• Fanconi Anemia: A complex genetic disorder affecting bone marrow.
• BAG3-DCM and PKP2-ACM: Inherited heart muscle diseases.

Rocket uses two main methods to deliver its therapies: Lentiviral (LV) vectors for diseases like LAD-I, Fanconi Anemia, and PKD, and Adeno-associated virus (AAV) vectors for cardiac conditions such as Danon Disease, BAG3-DCM, and PKP2-ACM. This dual approach allows Rocket to customize therapies for specific disease biology.

Pipeline Progress: Key Milestones in 2025

Rocket made significant advancements across its clinical pipeline this past year:

• LAD-I (RP-L201): This is Rocket's most advanced program. In 2025, Rocket continued enrolling patients in its pivotal Phase 2 study, presenting promising interim data showing sustained engraftment and clinical benefits for treated patients. Rocket expects to complete enrollment and potentially submit for regulatory approval in late 2026 or early 2027. The program benefits from special FDA designations like Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT), which can expedite development and review.
• Danon Disease (RP-A501): The Phase 1/2 study for this cardiac gene therapy progressed well, with initial data showing encouraging improvements in heart function and safety. Rocket plans further dose escalation and patient cohorts for 2026.
• Pyruvate Kinase Deficiency (RP-L301): Its Phase 1 study for PKD continued enrolling patients, with early safety and effectiveness data expected in mid-2026.
• Fanconi Anemia (RP-L102): The Phase 1/2 study continued, focusing on optimizing manufacturing processes and patient preparation methods.
• BAG3-DCM and PKP2-ACM: These programs remain in preclinical development. Studies required to start human trials (IND-enabling studies) are underway, with the goal of initiating clinical trials in 2027.

Financial Performance: A Look at the Numbers for FY2025

As a biotechnology company focused on clinical trials, Rocket Pharmaceuticals' financial performance shows significant investment in research and development:

• Revenue: For the fiscal year 2025, Rocket reported limited revenue of approximately $8.5 million, mainly from grants and collaboration agreements, not from product sales.
• Net Loss: Rocket reported a net loss of $285 million for 2025, an increase from the previous year. This rise primarily stemmed from expanded clinical trial activities, higher research and development expenses, and increased general and administrative costs as Rocket grew and advanced its pipeline.
• Research & Development (R&D) Expenses: R&D remained the largest expense, totaling $210 million in 2025. This reflects Rocket's commitment to advancing its pipeline.
• General & Administrative (G&A) Expenses: G&A expenses reached $75 million, supporting corporate operations, infrastructure, and activities before potential product launch.

Management's Discussion and Analysis (MD&A) Highlights

Management highlighted Rocket's strategic focus: advancing its lead programs toward pivotal studies and potential regulatory submissions. The significant increase in net loss and R&D expenses in 2025 directly resulted from increased investment in clinical trials for RP-L201 (LAD-I) and RP-A501 (Danon Disease, along with continued preclinical development for newer programs. Rocket considers this investment critical for achieving key clinical milestones and ultimately bringing therapies to market.

A capital raise in late 2024 strengthened Rocket's cash position. Management views this as essential to fund operations and R&D activities for the foreseeable future. Management emphasized careful spending to prioritize programs with the highest potential for near-term clinical and regulatory success, while also maintaining a strong preclinical pipeline. Rocket continues to monitor operational expenses closely to ensure efficient use of its funds.

Financial Health (Debt, Cash, Liquidity)

• Cash Position: As of December 31, 2025, Rocket held $350 million in cash, cash equivalents, and marketable securities. This cash is expected to fund operations into late 2026, based on current spending rates and planned expenditures.
• Debt: Rocket reported very little long-term debt as of December 31, 2025. It primarily relies on selling stock and grants to fund its operations.
• Liquidity: Rocket's cash on hand is considered sufficient to support its planned operations and R&D activities for the next 12 months, following the successful capital raise. However, Rocket expects to need additional funds to complete the development and potential commercialization of its product candidates.

Funding & Financial Strategy

Rocket Pharmaceuticals actively manages its funds to support extensive R&D efforts. In December 2024, Rocket successfully completed a public offering and private placement of common stock and warrants, raising approximately $150 million in gross proceeds. This influx of cash was crucial for funding ongoing clinical trials and preclinical development. While such offerings reduce the value of existing shareholders' stakes, they are a common and necessary way for biotech companies to finance their long and expensive development cycles before products reach the market.

Rocket also continues to benefit from non-dilutive funding (money that doesn't require issuing new stock) through strategic collaborations and grants. For example, grants from the California Institute for Regenerative Medicine (CIRM) for its LAD-I and Danon Disease programs validate Rocket's scientific approach and provide additional financial support.

Company Profile & Market Context

The SEC classifies Rocket Pharmaceuticals as a "Smaller reporting company" and a "Non-accelerated filer." This means its publicly traded shares are valued under $250 million, and it generally has fewer public reporting requirements compared to larger companies. While this can sometimes mean less detailed public information, it also reflects Rocket's growth stage, offering potential for significant upside if its therapies succeed.

As of February 20, 2026, Rocket had approximately 108.6 million shares of common stock outstanding. Its market capitalization on that date was approximately $250 million, reflecting investor sentiment about its pipeline and future potential.

Key Risks for Investors

Investing in a gene therapy company like Rocket Pharmaceuticals, which is still conducting clinical trials, carries natural risks:

• Clinical Trial Success: The primary risk is that Rocket's investigational therapies may fail to prove safe or effective in ongoing or future clinical trials.
• Regulatory Approval: Even with positive trial data, Rocket cannot guarantee regulatory approval from agencies like the FDA.
• Competition: The gene therapy landscape is highly competitive, with other companies developing similar or alternative treatments.
• Funding Needs: Rocket will likely need to raise additional capital in the future to fund continued R&D and potential product launches, which could further dilute existing shareholders.
• Intellectual Property: Protecting Rocket's proprietary technologies and therapies is critical. Challenges to its patents could impact its market position.
• Manufacturing & Commercialization: Scaling up manufacturing and successfully bringing approved therapies to market presents significant operational challenges.

Competitive Position

Rocket Pharmaceuticals operates in a highly competitive and rapidly evolving gene therapy landscape. Its competitive advantages include:

• Dual-Platform Approach: By using both Lentiviral and Adeno-associated virus vectors, Rocket can address a broader range of genetic diseases and customize therapies for specific biological needs, potentially gaining a competitive edge in certain areas.
• Focus on Ultra-Rare Diseases: By targeting diseases with significant unmet medical needs and small patient populations, Rocket may benefit from Orphan Drug designations and expedited regulatory pathways. These can reduce development timelines and provide market exclusivity.
• Early Clinical Progress: Rocket's lead program for LAD-I is in a pivotal Phase 2 study with promising interim data, positioning it as a potential first-mover in this area. Similarly, its progress in Danon Disease places it among the leaders in developing gene therapies for inherited heart muscle diseases.
• Proprietary Manufacturing Expertise: Rocket is investing in and developing its internal manufacturing capabilities and expertise for complex gene therapies. This can be a critical differentiator in terms of quality, cost, and supply chain control.

However, competition comes from other biotechnology and pharmaceutical companies developing gene therapies, gene-editing technologies, and other treatment approaches for similar or related genetic disorders. Rocket's ability to successfully compete will depend on factors such as clinical effectiveness, safety, regulatory success, manufacturing capabilities, intellectual property protection, and commercialization strategies.

Future Outlook (Guidance, Strategy)

Rocket Pharmaceuticals' strategy focuses on:

1. Accelerating Clinical Development: Prioritizing its most advanced programs, particularly LAD-I, toward regulatory submission and potential approval. This includes completing enrollment in pivotal studies and preparing applications for market approval (BLA/MAA).
2. Expanding the Pipeline: Advancing promising preclinical programs, such as BAG3-DCM and PKP2-ACM, into clinical trials to build a strong and diversified portfolio of gene therapies.
3. Strategic Partnerships: Exploring collaborations to potentially reduce development risks, share costs, or support future product launches, especially for broader market access.
4. Manufacturing Excellence: Investing in internal and external manufacturing capabilities and process development to ensure a reliable, scalable, and cost-effective supply of its complex gene therapies for clinical and commercial needs.

Rocket is committed to addressing the urgent needs of patients with rare genetic diseases, aiming to bring transformative, potentially curative, therapies to market. While Rocket does not provide specific financial guidance (e.g., revenue projections) given its clinical stage, its focus remains on achieving critical clinical and regulatory milestones to drive long-term value. Its current cash position should fund operations into late 2026, after which additional capital will likely be required.

Rocket Pharmaceuticals represents an investment in cutting-edge science with the potential to significantly impact patients' lives. While its financial performance reflects a company heavily invested in R&D and incurring substantial losses, progress in its clinical pipeline and strategic funding efforts provide a foundation for future growth. Investors should carefully consider the natural risks associated with biotechnology development alongside the potential for groundbreaking medical advancements.